Lee's Pharmaceutical Holdings Limited

Even more immuno-oncology antibodies may be coming in China as two new drug applications from domestic biopharmaceutical companies have been filed with the national regulatory agency. Hong Kong-listed

The pharma and biotech R&D pipeline experienced its largest ever expansion in 2019, growing by 9.6% to reach 17,737 products in active development, a new analysis by Citeline’s drug database Pharmapro

The ongoing US government shutdown means that the Securities and Exchange Commission (SEC) can't process new filings for proposed stock offerings, which means that the usual rush of biopharmaceutical

The South Korean pharma industry could be in for some pleasant surprises this year as several new pipeline drugs are slated to receive approvals from the US FDA or reveal their potential through key r